Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Retraction Note

Retraction Note to: Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations

Authors: Ming Ma, Guo-Jiang Jin, Ke Yun, Run-Qing Mu, Min Zhao, Xiao-Ou Yu, Shuo Wang, Hong Shang

Published in: Tumor Biology | Issue 9/2015

Login to get access

Excerpt

Retraction Note to: Tumor Biol. (2015) 36:807–814 …
Metadata
Title
Retraction Note to: Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations
Authors
Ming Ma
Guo-Jiang Jin
Ke Yun
Run-Qing Mu
Min Zhao
Xiao-Ou Yu
Shuo Wang
Hong Shang
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3787-2

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Retraction Note

Retraction Note to: A comprehensive analysis of candidate genes and pathways in pancreatic cancer

Research Article

Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study

Research Article

Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer

Research Article

The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer

Retraction Note

Retraction Note to: Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population

Retraction Note

Retraction Note to: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits